ÐÏà¡±á>þÿ :<þÿÿÿ9ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿì¥ÁÀ ð¿¤bjbjñ¡ñ¡ 4$“Ë“Ë¤ ÿÿÿÿÿÿ·((‚‚‚‚‚ÿÿÿÿ––––,Â–s%<ÞÞÞÞÞÍÍÍò$ô$ô$ô$ô$ô$ô$$¯'²a*R%‚ÍÍÍÍÍ%‚‚ÞÞï-%ÕÕÕÍ.‚Þ‚Þò$ÕÍò$ÕÕŽ"øÜ#ÞÿÿÿÿPÒ£pwÀÐÿÿÿÿû#Þ$C%0s%#Ä³*Ä³* Ü#Ü#&³*‚$ÜÍÍÕÍÍÍÍÍ%%ÕÍÍÍs%ÍÍÍÍÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ³*ÍÍÍÍÍÍÍÍÍ( H: DRUG DISCOVERY AND DEVELOPMENT (MSc/PgDip/PgCert) 57B220B1/61B220VX/62B220VZ Duration: 12 months full-time (MSc); 9 months full-time or 18 months part-time (PgDip). Aim: To equip students for careers developing and expanding our current knowledge of drug discovery and development. To achieve this, the programme will provide a multi-disciplinary approach to the study of drug discovery and development; mechanisms of drug action; preclinical and clinical trials; and regulatory affairs. Content: The programme of taught courses will comprise lectures, tutorials, practical classes and demonstrations. The curriculum includes biochemical and molecular aspects of drug action; drug transport, metabolism and excretion; toxicology; pharmacokinetics; computing studies; industrial aspects of drug development; therapeutic drug monitoring; the influence of disease on drug handling; drug-drug interactions; the design and conduct of volunteer and clinical trials; monitoring drug safety and an understanding of drug regulation. In addition, the programme includes Bio-Business which aims to bring the ideas and concepts of the commercialisation of scientific ideas to the student. Candidates shall be required to attend the following designated programme of courses: Stage 1 MT5010 Basic Skills Induction (0 credit points) MT5003 Drug Metabolism and Toxicology (15 credit points) BT5010 Small Molecule Drug Discovery (25 credit points) BT5012 Introduction to Bio-Business and the Commercialisation of Bioscience Research (15 credit points) GS50M1 Generic Skills for Taught Postgraduate Students (0 credit points) Plus one of the following electives MB5022 Introduction to Molecular Biology (15 credit points) Or MT5024 Molecular Pharmacology (15 c credit points) Or PU5017 Applied Statistics (15 credit points) Stage 2 BT5508 Advanced Bio-Business and the Commercialisation of Bioscience Research (15 credit points) BT5502 Special Study Module 2: Biologic therapies (25 credit points) MT5518 Pharmacokinetics (15 credit points) MT5515 Basic Research Methods (15 credit points) Above courses contribute to degree award. The following courses are available as additional optional credits MT5501 Pharmacovigilance (5 credit points) Stage 3 MT5903 Research Project (60 credit points) Assessment: By practical work, by written essays, written examinations and by oral presentations, or by a combination of these, as prescribed for each course. The project will be assessed on the basis of performance, written thesis, and oral presentation. There will usually be an oral examination to complete the programme. Candidates must pass all courses at an appropriate standard for the award of the MSc degree. 2MNW¨¬î ö ¢ùú ! ' 1 2 3 O íÛíÉµ¤¤n\NN*CJOJQJ^JaJh¬NÈCJOJQJ^JaJ#hÿ(÷h½s¾>*CJOJQJ^JaJ hÿ(÷h9’CJOJQJ^JaJ hÿ(÷h–ãCJOJQJ^JaJ&hÿ(÷h–ã6CJOJQJ]^JaJ hÿ(÷hxìCJOJQJ^JaJ&hÿ(÷hxì6CJOJQJ]^JaJ#hÿ(÷h9’5CJOJQJ^JaJ#hÿ(÷hxì5CJOJQJ^JaJ#hÿ(÷h:;¨5CJOJQJ^JaJ2MN§¨í î ¢£ùú 3 l ¤ òåòòØËËË¹¹ò¯¯¡“““ ÆSdð¤gdoA ÆSdð¤gdfÒ dð¤gd½s¾$ Æ0dð¤a$gd:;¨$dð¤a$gd¤.Ð$dð¤a$gd–ã$dð¤a$gd:;¨$dð¤a$gd:;¨O ] ` j l ˆ • ˜ ¢ £ ¤ ª ± æ ú ý !BFISTUV[|©¬¶·¸¹¼ÀïÞÐïÐïÞÐÞï¿ïÐï¿ÞÐÞï®ïÞÐÞïœŠœïÞÐÞÐxfï#h¬NÈh½s¾6CJOJQJ^JaJ#h¬NÈh¬NÈ6CJOJQJ^JaJ#hÿ(÷hÚÞ6CJOJQJ^JaJ#hÿ(÷h½s¾6CJOJQJ^JaJ hÿ(÷hÚÞCJOJQJ^JaJ hÿ(÷h†2-CJOJQJ^JaJh¬NÈCJOJQJ^JaJ hÿ(÷h¬NÈCJOJQJ^JaJ hÿ(÷h½s¾CJOJQJ^JaJ$UV|¸¼ïò ()ŠÏú+,š›ÆÇÏÐñßñññññññññññññÑÀñññññ ÆS„dð¤gdoA ÆSdð¤gd¬NÈ ÆS„Ðdð¤^„ÐgdoA ÆSdð¤gdoAÀÂÎßàãíîïò )/O\o{~ˆ‘©ÀÃÍÓÕéêëîøúïáÐ¿®á® Žá®áÐ|ÐáÐáÐ®áÐnÐ®áÐ]Ð]Ð®áÐáÐ hÿ(÷hOBCJOJQJ^JaJhâCJOJQJ^JaJ#hÿ(÷h½s¾>*CJOJQJ^JaJ#h¬NÈh¬NÈ6CJOJQJ^JaJh½s¾CJOJQJ^JaJ hÿ(÷h¬NÈCJOJQJ^JaJ h¬NÈh¬NÈCJOJQJ^JaJ hÿ(÷h½s¾CJOJQJ^JaJh¬NÈCJOJQJ^JaJ hÿ(÷hß|cCJOJQJ^JaJ$),ˆ‘š·ºÄÇÐìïùúûü-C¢ïáÐÀ³ÀÐïáÐ¡ÐïáÐ~j~Y~Jhÿ(÷h–ãCJOJQJaJ hÿ(÷hÝd4CJOJQJ^JaJ&hÿ(÷hxì6CJOJQJ]^JaJ hÿ(÷hxìCJOJQJ^JaJ#hÿ(÷h½s¾5CJOJQJ^JaJ#hÿ(÷h½s¾>*CJOJQJ^JaJhKô6CJOJQJaJhÿ(÷h½s¾6CJOJQJaJ hÿ(÷h½s¾CJOJQJ^JaJh¬NÈCJOJQJ^JaJ hÿ(÷h¬NÈCJOJQJ^JaJÐûüž£¤ñàÑÑÀ$ Æ„d¤a$gd–ã Æ0dð¤gd¤.Ð$ Æ„d¤a$gd:;¨ ÆSdð¤gdoA¢£¤ïÝ#h:;¨hxì5CJOJQJ^JaJ hÿ(÷h–ãCJOJQJ^JaJ21h:p·5°‚. °ÆA!° "° # $ %°°Ä°ÄÄj˜žžžžžžž666666666vvvvvvvvv666666>666666666666666666666666666¨6666666666¸666666666666hH66666666666666666666666666666666666666666666666666666666666666666°62ÀÐàð 0@P`p€ÀÐàð2(Øè 0@P`p€ÀÐàð 0@P`p€ÀÐàð 0@P`p€ÀÐàð 0@P`p€ÀÐàð 0@P`p€ÀÐàð 0@P`p€8XøV~ OJPJQJ_HmH nH sH tH J`ñÿJ9’Normald¤ÈCJ_HaJmH sH tH ^@^xì Heading 2$dð¤@&a$>*CJOJPJQJ^JaJDA òÿ¡D Default Paragraph FontRióÿ³R0Table Normalö4Ö l4Öaö(k ôÿÁ( 0No List@³ò@9’ List Paragraph ^„Ðm$R™@R \0Balloon Textdð¤CJOJQJ^JaJNþoòÿN\0Balloon Text CharCJOJQJ^JaJPþoòÿ!PxìHeading 2 Char>*CJOJPJQJ^JaJPK!éÞ¿ÿ[Content_Types].xml¬‘ËNÃ0E÷Hüƒå-Jœ²@%é‚ÇŽÇ¢|ÀÈ™$ÉØ²§Uû÷LÒTB¨ l,Ù3÷ž;ãr½µÃ˜œ§J¯òB+$ëG]¥ß7OÙV‰$ùãûÿ©«×îÇ!)OÚ^ýrÍC$ñy@“°íÝö/yH*œ˜ñ„´½)‘Þµ÷ß»Š×UDb‚`}"×qÛ‹”J×—–¤ÃX^æ)I`nÌEŒ¼Šp)øèÆli¹V[]Š1M<”àÈÞ©OÐP“ô6râ=¯‰’zÀgb Ig…ÁuSÙebÖö€OÀ†ä¾òÃRÁDÛ«™Ÿ·´qu ¯g‹˜Z°¶´®o~ÙºlAp°lxŠpT0÷+[}`j×ëõº½zAÏ°ïƒ¦V–2ÍFÞÉi–@öqžv·Ö¬5\|‰þÊœÌN§Óle²X¢dsøµÚjcsÙÁÅ7çðÎf·»êà ÈâWçðý+Õ†‹7 ˆÑä`ÚïgÔÈ˜³íJøÀ×j|†‚h(¢K³óD-Šµßã¢ dXÑ©iJÆØ‡(îâx$(Öð:Á¥;äË¹!ÍI_ÐTµ½S1£÷êù÷¯ž?EÇž?øéøáÃã?ZBÎªmœ„åU/¿ýìÏÇ£?ž~óòÑÕxYÆÿúÃ'¿üüy5Òg&Î‹/ŸüöìÉ‹¯>ýý»GðMGeøÆD¢›äíó3Vq%'#q¾ÃÓòŠÍ$”8ÁšKýžŠôÍ)f™w9:Äµàå£ x}rÏx‰‰¢œw¢ØîrÎ:\TZaGó*™y8IÂjæbRÆíc|XÅ»‹Ç¿½I u3KGñnD1÷NIBÒsü€ íîRêØu—ú‚K>Vè.EL+M2¤#'šf‹¶i~™Véþvl³{u8«Òz‹ºHÈ Ì*„æ˜ñ:ž(W‘â˜• ~«¨JÈÁTøe\O*ðtHG½€HYµæ–}KNßÁP±*Ý¾Ë¦±‹ŠTÑ¼9/#·øA7ÂqZ…Ð$*c?¢íqUßån†èwðNºû%Ž»O¯·ièˆ4=3¾¼N¸¿ƒ)cbJ u§VÇ4ù»ÂÍ(TnËáâ 7”Ê_?®ûm-Ù›°{UåÌö‰B½w²ÒzÏû¨nœ”ÇÊœ"ZúàxŠÕJÜZšìp;‹“ÊìØåÞ{/å<óP;™Ž,)''KÐQÛk5—›òqÚöÆpN†Ç8¯KÝGbÂe“¯„ ûS“ÙdùÌ›\17 êpõaí>§°SR!Õ–‘ 3•…K4'+ÿrÌzQ TT£³I±²Áð¯Ivt]KÆcâ«²³K#Úvö5+¥|¢ˆDÁ±‰ØÇà~ª O@%\w˜Š _ànN[ÛL¹Å9Kºò˜ÁÙqÌÒgåV§hžÉn R!ƒy+‰ºUÊn”;¿*&å/H•rÿÏTÑû Ü>¬Ú>\ Œt¦´=.TÄ¡ ¥õûS; Zà~¦!¨à‚ÚüäPÿ·9gi˜´†C¤Ú§!ö# Bö ,™è;…X=Û»,I–2UW¦Vì9$l¨kàªÞÛ=A¨›j’•ƒ;î{–A£P79å|s*Y±÷Úø§;›Ì ”[‡MC“Û¿±hf»ª]o–ç{oY=1k³yV³ÒVÐÊÒþ5E8çVk+ÖœÆËÍ\8ðâ¼Æ0X4D)Ü!!ýö?*|f¿vè uÈ÷¡¶"øx¡‰AØ@T_²ÒÒŽ q²ƒ6˜4)kÚ¬uÒVË7ëît¾'Œ%;‹¿Ïiì¢9sÙ9¹x‘ÆÎ,ìØÚŽ-45xödŠÂÐ8?ÈÇ˜Ïdå/Y|t½ß&LILðJ`è¡& ù-G³tã/ÿÿPK! ÑŸ¶'theme/theme/_rels/themeManager.xml.rels„M Â0„÷‚wooÓº‘&ÝˆÐÔ„ä5 6?$Qìí ®,.‡a¾™i»—Éc2Þ1hª:é•qšÁm¸ìŽ@RN‰Ù;d°`‚Žo7íg‘K(M&$R(.1˜r'J“œÐŠTù€®8£Vä"£¦AÈ»ÐH÷u} ñ›|Å$½b{Õ–Pšÿ³ý8‰g/]þQAsÙ…(¢ÆÌà#›ªLÊ[ººÄßÿÿPK-!éÞ¿ÿ[Content_Types].xmlPK-!¥Ö§çÀ60_rels/.relsPK-!ky–ƒŠtheme/theme/themeManager.xmlPK-!0ÝC)¨¤Ötheme/theme/theme1.xmlPK-! ÑŸ¶'² theme/theme/_rels/themeManager.xml.relsPK] ¤ $ÿÿÿÿO À¢¤ Ð¤ ðLð#ð†ÁÅÁ@ñÿÿÿ€€€÷ð’ðð0ð( ð ððB ðSð¿Ëÿ ?ð$)*0‘˜¦ V_¦ 3NNmm)){ˆ‰‰ŠŠ‘©ÀÍëø)++ˆ‘·Äìù£ ¦ ãL>ºÚäÿÿÿÿÿÿÿÿÿIk²;ÆVš)ÿÿÿÿÿÿÿÿÿ5G¤B+ìÿÿÿÿÿÿÿÿÿ0¬j” šÿÿÿÿÿÿÿÿÿõsÃ}À‹ ›ÿÿÿÿÿÿÿÿÿ„Ð„˜þÆÐ^„Ð`„˜þOJQJ^Jo(" „ „˜þÆ ^„ `„˜þOJQJ^Jo( „p„˜þÆp^„p`„˜þ.„@„˜þÆ@^„@`„˜þ.„„˜þÆ^„`„˜þ.„à„˜þÆà^„à`„˜þ.„°„˜þÆ°^„°`„˜þ.„€„˜þÆ€^„€`„˜þ.„P„˜þÆP^„P`„˜þ.„ „˜þ^„ `„˜þOJQJo(·ð€„p„˜þ^„p`„˜þOJQJ^Jo(o€„@„˜þ^„@`„˜þOJQJo(§ð€„„˜þ^„`„˜þOJQJo(·ð€„à„˜þ^„à`„˜þOJQJ^Jo(o€„°„˜þ^„°`„˜þOJQJo(§ð€„€„˜þ^„€`„˜þOJQJo(·ð€„P„˜þ^„P`„˜þOJQJ^Jo(o€„ „˜þ^„ `„˜þOJQJo(§ð„Ð„˜þÆÐ^„Ð`„˜þOJQJ^Jo(" #„ „˜þÆ ^„ `„˜þOJQJ^Jo( „p„˜þÆp^„p`„˜þ.„@„˜þÆ@^„@`„˜þ.„„˜þÆ^„`„˜þ.„à„˜þÆà^„à`„˜þ.„°„˜þÆ°^„°`„˜þ.„€„˜þÆ€^„€`„˜þ.„P„˜þÆP^„P`„˜þ.„Ð„˜þ^„Ð`„˜þCJOJQJaJo(·ð€„ „˜þ^„ `„˜þOJQJ^Jo(o€„p„˜þ^„p`„˜þOJQJo(§ð€„@„˜þ^„@`„˜þOJQJo(·ð€„„˜þ^„`„˜þOJQJ^Jo(o€„à„˜þ^„à`„˜þOJQJo(§ð€„°„˜þ^„°`„˜þOJQJo(·ð€„€„˜þ^„€`„˜þOJQJ^Jo(o€„P„˜þ^„P`„˜þOJQJo(§ð„Ð„˜þ^„Ð`„˜þOJQJo(·ð€„ „˜þ^„ `„˜þOJQJ^Jo(o€„p„˜þ^„p`„˜þOJQJo(§ð€„@„˜þ^„@`„˜þOJQJo(·ð€„„˜þ^„`„˜þOJQJ^Jo(o€„à„˜þ^„à`„˜þOJQJo(§ð€„°„˜þ^„°`„˜þOJQJo(·ð€„€„˜þ^„€`„˜þOJQJ^Jo(o€„P„˜þ^„P`„˜þOJQJo(§ðãL> 5G¤B Ik²;0¬jõsÃ}ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿbvtÂÜ‰x:á–,~VP$ÖÛP…$c@%âýZärfM<¹— (N2HndµJ`TôÖÊúÚœ\þ¶à`n,þœ/ò¼.¬Î¤ÔV \ 4/Y_1å ÈBâO`/)†2- v3Ýd4·5<;oAOBôCJ²(P+X\MaÓrcß|c¶+iCmn³Bwo ß!‡9’›'¤:;¨u)³å)³°Qµ½s¾lÂ¬NÈÓQÉ¤.ÐfÒësÖ!\Ú«ÛÚÞ–ãópèxìEîKôÿ(÷þ6ú cþ¤ ¦ ÿ@€‘‘‘‘¤ ˜@ÿÿUnknownÿÿÿÿÿÿÿÿÿÿÿÿ Gÿ*àAxÀ ÿTimes New Roman5€Symbol3.ÿ*àCxÀ ÿArial7.ÿáÿ¬@ ŸCalibriY CG TimesTimes New Roman5.ÿ.á[`À)ÿTahoma?= ÿ*àCxÀ ÿCourier New;€WingdingsAÿàÿ$BŸCambria Math"qˆðÐh…ó'ÀŠ7§ó'– – !ð ´´20Ÿ Ÿ 3ƒQðüýHX ðÿ $Päÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ9’2!xx ÜÿÿMelanie McCannadr152 þÿà…ŸòùOh«‘+'³Ù0t˜¤°ÈÔè ø $0< HT\dläMelanie McCannNormal.dotmadr15221Microsoft Office Word@î @Ná]SnÍ@fîìSnÍ@PÆWwÀÐ– þÿÕÍÕœ.“—+,ù®DÕÍÕœ.“—+,ù®@ühp˜ ¨°¸ÀÈ ÐÝä51cgŸ TitlexHìô0Pl_NewReviewCycle_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayName_ReviewingToolsShownOnceäÕ"ª SENAS: New programme proposalr.j.findlay@abdn.ac.ukFindlay, Robert J þÿÿÿ !"#$%&'(þÿÿÿ*+,-./0þÿÿÿ2345678þÿÿÿýÿÿÿ;þÿÿÿþÿÿÿþÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿRoot Entryÿÿÿÿÿÿÿÿ ÀF0¹¯pwÀÐ=€1TableÿÿÿÿÿÿÿÿÓ*WordDocumentÿÿÿÿÿÿÿÿ4$SummaryInformation(ÿÿÿÿ)DocumentSummaryInformation8ÿÿÿÿÿÿÿÿÿÿÿÿ1CompObjÿÿÿÿÿÿÿÿÿÿÿÿrÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿþÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿþÿ ÿÿÿÿ ÀF Microsoft Word 97-2003 Document MSWordDocWord.Document.8ô9²q